The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Neurodegenerative Disease-Global Market Insights and Sales Trends 2025
Synopsis
Neurodegenerative diseases are a group of disorders characterized by the progressive degeneration of the structure and function of the nervous system, leading to cognitive and motor impairments. Examples include Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
The global Neurodegenerative Disease market size is expected to reach US$ 8704 million by 2029, growing at a CAGR of 3.1% from 2023 to 2029. The market is mainly driven by the significant applications of Neurodegenerative Disease in various end use industries. The expanding demands from the Parkinson’s Disease, Huntington Disease, Amyotrophic Lateral Sclerosis and Alzheimer’s Disease, are propelling Neurodegenerative Disease market. NMDA, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the SSRIs segment is estimated at % CAGR for the next seven-year period.
The market for neurodegenerative disease treatments and management is driven by the increasing prevalence of these diseases, particularly with an aging population. The market's growth is also influenced by the demand for disease-modifying therapies and symptom management options to improve the quality of life for patients.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Neurodegenerative Disease, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Neurodegenerative Disease market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Neurodegenerative Disease market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Neurodegenerative Disease sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Neurodegenerative Disease covered in this report include Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi and GlaxoSmithKline, etc.
The global Neurodegenerative Disease market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
Global Neurodegenerative Disease market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Neurodegenerative Disease market, Segment by Type:
NMDA
SSRIs
Dopamine Inhibitors
Global Neurodegenerative Disease market, by Application
Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Neurodegenerative Disease companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Neurodegenerative diseases are a group of disorders characterized by the progressive degeneration of the structure and function of the nervous system, leading to cognitive and motor impairments. Examples include Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
The global Neurodegenerative Disease market size is expected to reach US$ 8704 million by 2029, growing at a CAGR of 3.1% from 2023 to 2029. The market is mainly driven by the significant applications of Neurodegenerative Disease in various end use industries. The expanding demands from the Parkinson’s Disease, Huntington Disease, Amyotrophic Lateral Sclerosis and Alzheimer’s Disease, are propelling Neurodegenerative Disease market. NMDA, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the SSRIs segment is estimated at % CAGR for the next seven-year period.
The market for neurodegenerative disease treatments and management is driven by the increasing prevalence of these diseases, particularly with an aging population. The market's growth is also influenced by the demand for disease-modifying therapies and symptom management options to improve the quality of life for patients.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Neurodegenerative Disease, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Neurodegenerative Disease market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Neurodegenerative Disease market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Neurodegenerative Disease sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Neurodegenerative Disease covered in this report include Novartis, Pfizer, Merck Serono, Biogen Idec, TEVA, UCB, Boehringer Ingelheim, Sanofi and GlaxoSmithKline, etc.
The global Neurodegenerative Disease market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
Global Neurodegenerative Disease market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Neurodegenerative Disease market, Segment by Type:
NMDA
SSRIs
Dopamine Inhibitors
Global Neurodegenerative Disease market, by Application
Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Neurodegenerative Disease companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Neurodegenerative Disease
1.1 Neurodegenerative Disease Market Overview
1.1.1 Neurodegenerative Disease Product Scope
1.1.2 Neurodegenerative Disease Market Status and Outlook
1.2 Global Neurodegenerative Disease Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Neurodegenerative Disease Market Size by Region (2018-2029)
1.4 Global Neurodegenerative Disease Historic Market Size by Region (2018-2023)
1.5 Global Neurodegenerative Disease Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Neurodegenerative Disease Market Size (2018-2029)
1.6.1 North America Neurodegenerative Disease Market Size (2018-2029)
1.6.2 Europe Neurodegenerative Disease Market Size (2018-2029)
1.6.3 Asia-Pacific Neurodegenerative Disease Market Size (2018-2029)
1.6.4 Latin America Neurodegenerative Disease Market Size (2018-2029)
1.6.5 Middle East & Africa Neurodegenerative Disease Market Size (2018-2029)
2 Neurodegenerative Disease Market by Type
2.1 Introduction
2.1.1 NMDA
2.1.2 SSRIs
2.1.3 Dopamine Inhibitors
2.2 Global Neurodegenerative Disease Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Neurodegenerative Disease Historic Market Size by Type (2018-2023)
2.2.2 Global Neurodegenerative Disease Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Neurodegenerative Disease Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Neurodegenerative Disease Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Neurodegenerative Disease Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Neurodegenerative Disease Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Neurodegenerative Disease Revenue Breakdown by Type (2018-2029)
3 Neurodegenerative Disease Market Overview by Application
3.1 Introduction
3.1.1 Parkinson’s Disease
3.1.2 Huntington Disease
3.1.3 Amyotrophic Lateral Sclerosis
3.1.4 Alzheimer’s Disease
3.2 Global Neurodegenerative Disease Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Neurodegenerative Disease Historic Market Size by Application (2018-2023)
3.2.2 Global Neurodegenerative Disease Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Neurodegenerative Disease Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Neurodegenerative Disease Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Neurodegenerative Disease Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Neurodegenerative Disease Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Neurodegenerative Disease Revenue Breakdown by Application (2018-2029)
4 Neurodegenerative Disease Competition Analysis by Players
4.1 Global Neurodegenerative Disease Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neurodegenerative Disease as of 2022)
4.3 Date of Key Players Enter into Neurodegenerative Disease Market
4.4 Global Top Players Neurodegenerative Disease Headquarters and Area Served
4.5 Key Players Neurodegenerative Disease Product Solution and Service
4.6 Competitive Status
4.6.1 Neurodegenerative Disease Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Novartis
5.1.1 Novartis Profile
5.1.2 Novartis Main Business
5.1.3 Novartis Neurodegenerative Disease Products, Services and Solutions
5.1.4 Novartis Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.1.5 Novartis Recent Developments
5.2 Pfizer
5.2.1 Pfizer Profile
5.2.2 Pfizer Main Business
5.2.3 Pfizer Neurodegenerative Disease Products, Services and Solutions
5.2.4 Pfizer Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.2.5 Pfizer Recent Developments
5.3 Merck Serono
5.3.1 Merck Serono Profile
5.3.2 Merck Serono Main Business
5.3.3 Merck Serono Neurodegenerative Disease Products, Services and Solutions
5.3.4 Merck Serono Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.3.5 Biogen Idec Recent Developments
5.4 Biogen Idec
5.4.1 Biogen Idec Profile
5.4.2 Biogen Idec Main Business
5.4.3 Biogen Idec Neurodegenerative Disease Products, Services and Solutions
5.4.4 Biogen Idec Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.4.5 Biogen Idec Recent Developments
5.5 TEVA
5.5.1 TEVA Profile
5.5.2 TEVA Main Business
5.5.3 TEVA Neurodegenerative Disease Products, Services and Solutions
5.5.4 TEVA Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.5.5 TEVA Recent Developments
5.6 UCB
5.6.1 UCB Profile
5.6.2 UCB Main Business
5.6.3 UCB Neurodegenerative Disease Products, Services and Solutions
5.6.4 UCB Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.6.5 UCB Recent Developments
5.7 Boehringer Ingelheim
5.7.1 Boehringer Ingelheim Profile
5.7.2 Boehringer Ingelheim Main Business
5.7.3 Boehringer Ingelheim Neurodegenerative Disease Products, Services and Solutions
5.7.4 Boehringer Ingelheim Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.7.5 Boehringer Ingelheim Recent Developments
5.8 Sanofi
5.8.1 Sanofi Profile
5.8.2 Sanofi Main Business
5.8.3 Sanofi Neurodegenerative Disease Products, Services and Solutions
5.8.4 Sanofi Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.8.5 Sanofi Recent Developments
5.9 GlaxoSmithKline
5.9.1 GlaxoSmithKline Profile
5.9.2 GlaxoSmithKline Main Business
5.9.3 GlaxoSmithKline Neurodegenerative Disease Products, Services and Solutions
5.9.4 GlaxoSmithKline Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.9.5 GlaxoSmithKline Recent Developments
5.10 Livzon Pharmaceutical
5.10.1 Livzon Pharmaceutical Profile
5.10.2 Livzon Pharmaceutical Main Business
5.10.3 Livzon Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
5.10.4 Livzon Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.10.5 Livzon Pharmaceutical Recent Developments
5.11 Haisco Pharmaceutical
5.11.1 Haisco Pharmaceutical Profile
5.11.2 Haisco Pharmaceutical Main Business
5.11.3 Haisco Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
5.11.4 Haisco Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.11.5 Haisco Pharmaceutical Recent Developments
5.12 Jingxin Pharmaceutical
5.12.1 Jingxin Pharmaceutical Profile
5.12.2 Jingxin Pharmaceutical Main Business
5.12.3 Jingxin Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
5.12.4 Jingxin Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.12.5 Jingxin Pharmaceutical Recent Developments
5.13 Dongcheng Biochemicals
5.13.1 Dongcheng Biochemicals Profile
5.13.2 Dongcheng Biochemicals Main Business
5.13.3 Dongcheng Biochemicals Neurodegenerative Disease Products, Services and Solutions
5.13.4 Dongcheng Biochemicals Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.13.5 Dongcheng Biochemicals Recent Developments
5.14 Hisun Pharmaceutical
5.14.1 Hisun Pharmaceutical Profile
5.14.2 Hisun Pharmaceutical Main Business
5.14.3 Hisun Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
5.14.4 Hisun Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.14.5 Hisun Pharmaceutical Recent Developments
5.15 Luye Pharma
5.15.1 Luye Pharma Profile
5.15.2 Luye Pharma Main Business
5.15.3 Luye Pharma Neurodegenerative Disease Products, Services and Solutions
5.15.4 Luye Pharma Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.15.5 Luye Pharma Recent Developments
5.16 Ark Pharmaceutical
5.16.1 Ark Pharmaceutical Profile
5.16.2 Ark Pharmaceutical Main Business
5.16.3 Ark Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
5.16.4 Ark Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.16.5 Ark Pharmaceutical Recent Developments
5.17 Kanghong Pharmaceutical
5.17.1 Kanghong Pharmaceutical Profile
5.17.2 Kanghong Pharmaceutical Main Business
5.17.3 Kanghong Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
5.17.4 Kanghong Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.17.5 Kanghong Pharmaceutical Recent Developments
5.18 Huahai Pharmaceutical
5.18.1 Huahai Pharmaceutical Profile
5.18.2 Huahai Pharmaceutical Main Business
5.18.3 Huahai Pharmaceutical Neurodegenerative Disease Products, Services and Solutions
5.18.4 Huahai Pharmaceutical Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.18.5 Huahai Pharmaceutical Recent Developments
5.19 BORA PHARMACEUTICALS
5.19.1 BORA PHARMACEUTICALS Profile
5.19.2 BORA PHARMACEUTICALS Main Business
5.19.3 BORA PHARMACEUTICALS Neurodegenerative Disease Products, Services and Solutions
5.19.4 BORA PHARMACEUTICALS Neurodegenerative Disease Revenue (US$ Million) & (2018-2023)
5.19.5 BORA PHARMACEUTICALS Recent Developments
6 North America
6.1 North America Neurodegenerative Disease Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Neurodegenerative Disease Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Disease Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Neurodegenerative Disease Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Disease Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Neurodegenerative Disease Market Dynamics
11.1 Neurodegenerative Disease Industry Trends
11.2 Neurodegenerative Disease Market Drivers
11.3 Neurodegenerative Disease Market Challenges
11.4 Neurodegenerative Disease Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
